Three new treatments for dry eye disease and a new procedure and remote monitoring platform for glaucoma are due to debut in 2024, with more in the pipeline.
Richard Adler, MD, FACS, provides perspective on AAO 2023 data suggesting dual mechanism treatment targeting aqueous deficiency and meibomian gland dysfunction may improve dry eye symptoms more significantly and faster than singular therapies, benefiting patient compliance and disease management.
In this discussion with E. James Song, MD, several unique clinical pearls for those in dermatology were described and had been drawn from Song’s Winter Clinical presentation.
A significant number of patients with moderate to severe atopic dermatitis (AD) failed to achieve adequate disease control with systemic therapies over 12 months, indicating a substantial degree of "therapeutic inertia."
VEVYE is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks Novaliq GmbH, a biopharmaceutical company